X4 Pharmaceuticals Inc - XFOR STOCK NEWS

X4 Pharmaceuticals (Nasdaq: XFOR) announced on March 1, 2022, that its Compensation Committee granted inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. This includes options to purchase 22,250 shares and restricted stock units for 3,500 shares. The options have a ten-year term with an exercise price of $1.50 per share, vesting over four years. X4 focuses on developing novel therapies for immune system dysfunction, with its lead candidate mavorixafor currently in global Phase 3 trials and addressing rare diseases like WHIM syndrome.

X4 Pharmaceuticals (XFOR) announced the issuance of inducement awards to new employees as part of its 2019 Inducement Equity Incentive Plan. On January 31, 2022, the Compensation Committee granted options to purchase 33,000 shares and restricted stock units covering 11,000 shares of common stock. The options have a ten-year term with an exercise price of $2.06, vesting over four years. X4 is developing novel therapies for immune dysfunction, with its lead candidate, mavorixafor, undergoing Phase 3 trials for WHIM syndrome.

X4 Pharmaceuticals, a leader in immune system therapeutics, will participate in a fireside chat at the B. Riley Securities Oncology Investor Conference on January 28, 2022, at 1:00 PM ET. The conference will focus on their innovative therapies, including the lead candidate mavorixafor, a novel CXCR4-targeted small molecule. A live webcast will be available on their website, where it will remain archived for 30 days post-event. X4 Pharmaceuticals is dedicated to advancing treatments for various immune system dysfunctions and has ongoing clinical trials for its lead candidate.

Sporos Bioventures has announced the formation of a Strategic Advisory Board (SAB), chaired by Douglas E. Williams, Ph.D. The inaugural members include leading experts in precision oncology and immunology: Keith T. Flaherty, M.D., Bing Yao, Ph.D., and Douglas Hanahan, Ph.D. The SAB will support Sporos in advancing its research portfolio targeting unmet medical needs in cancer and immune diseases. This initiative reflects the company's commitment to innovation and collaboration in drug development.

X4 Pharmaceuticals (Nasdaq: XFOR) announced inducement awards to new employees under the 2019 Inducement Equity Incentive Plan on December 31, 2021. The awards comprise options for 37,650 shares, with an exercise price of $2.40 per share, equal to the closing price on January 4, 2022. The options will vest over four years, with 25% vesting after one year. X4 focuses on developing novel therapies targeting the CXCR4 pathway, particularly for rare diseases. Its lead candidate, mavorixafor, is being evaluated in multiple clinical trials, including a Phase 3 trial for WHIM syndrome.

X4 Pharmaceuticals (Nasdaq: XFOR) recently presented positive findings on mavorixafor at the ASH Annual Meeting. The data indicates that mavorixafor effectively raises white blood cell counts across various diseases, including Chronic Neutropenia and WHIM syndrome, showcasing sustained improvements in infection rates. Notably, mavorixafor has been well tolerated in ongoing clinical trials. A virtual seminar on this topic is scheduled for December 16, 2021. Results from a global Phase 3 trial in WHIM syndrome are expected by Q4 2022.

X4 Pharmaceuticals (Nasdaq: XFOR) announced positive interim results from its ongoing Phase 1b trial of mavorixafor in combination with ibrutinib for patients with Waldenström’s macroglobulinemia (WM) and specific mutations. The trial has achieved a remarkable 100% overall response rate in evaluable patients. After 12 months, patients saw significant reductions in serum IgM levels, with median decreases from 47.2 g/L to 7.73 g/L. Further data, including responses from refractory patients, is expected throughout 2022.

X4 Pharmaceuticals (Nasdaq: XFOR) is set to host a virtual seminar titled “Understanding Primary Immunodeficiencies” on December 16, 2021, at 8:30 a.m. EST. The seminar aims to showcase new clinical data on mavorixafor, their leading candidate for treating immunodeficiencies, particularly in the context of WHIM syndrome. Esteemed guest speakers include experts such as Neal Sondheimer, M.D., and Theresa Tarrant, M.D. The event will also highlight relevant research from the upcoming ASH Annual Meeting. A live webcast will be available on the company's website.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced on December 1, 2021, that its Compensation Committee granted inducement awards to new employees. These awards include options for 17,000 shares and restricted stock units for 25,000 shares under the 2019 Inducement Equity Incentive Plan. The options have a ten-year term with an exercise price of $4.45 per share, vesting over four years. X4 focuses on developing CXCR4-targeted therapies, notably mavorixafor, which is undergoing clinical trials for various immune system diseases.